Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients

Kenichiro Kinouchi, Atsuhiro Ichihara, Mariyo Sakoda, Asako Kurauchi-Mito, Kanako Murohashi-Bokuda, Hiroshi Itoh

研究成果: Article査読

33 被引用数 (Scopus)


Background/Aims: This study was conducted to determine the effect of telmisartan on the cardio-ankle vascular index (CAVI), a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods: One hundred consecutive hypertensive patients were randomly assigned either to a group treated with calcium channel blocker (CCB)-based therapy or a group treated with telmisartan-based therapy. Clinical and biological parameters were then measured before and 12 months after the start of this study. Results: CAVI, the logarithm of urinary albumin excretion, and BP were reduced significantly after telmisartan-based therapy. The decreases in 24-hour diastolic BP and daytime systolic BP associated with telmisartan-based therapy were significantly greater than those associated with CCB-based therapy. Both therapies significantly and similarly decreased the clinical BP, 24-hour systolic BP, daytime diastolic BP and serum levels of low-density lipoprotein cholesterol. No significant differences in the metabolic parameters were observed between the two therapies. Conclusion: Telmisartan-based therapy had beneficial effects on arterial stiffness assessed by CAVI, albuminuria, 24-hour BP and metabolism compared with CCB-based therapy. Since these markers are known to influence the future risk of cardiovascular events, telmisartan could be a useful drug for hypertensive patients.

ジャーナルKidney and Blood Pressure Research
出版ステータスPublished - 2010 8月

ASJC Scopus subject areas

  • 腎臓病学
  • 循環器および心血管医学


「Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。